Thus, the present study was done to assess prospectively the ovarian function and reserve in patients of severe lupus treated with CYC, by evaluating changes in menstrual function, hormonal profile [anti-Mullerian hormone (AMH), inhibin B, estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone (LH)], ovarian volume, and antral follicular count with 6 months of CYC therapy (primary objective). The gene discussed is AMH; the disease is systemic lupus erythematosus.